BCG resistance is hallmarked by the expression of immunosuppressive molecules: programmed death (PD)L1, PDL2 ligands by BCG resistant tumor engages with the PD1 receptor on T cells to suppress anti-tumor response [10] (Figure 1). The gene discussed is PDCD1LG2; the disease is neoplasm.